Project Grant R44GM163418
- Federal Grant Award Summary Cellfe, Inc. received a Phase I Small Business Innovation Research (SBIR) grant of $314,000 from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) for the period of September 1, 2025 through August 31, 2026. The company will conduct proof-of-concept research and development to optimize and validate the CellFE platform, a microfluidic transfection technology designed to enable...
- Federal Grant Award Summary Epitune LLC received a $350,000 Project Grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), awarded on September 16, 2025, with completion targeted for February 28, 2026. The award funds development of a novel imaging-based platform for single-cell quality and identity control of human-induced pluripotent stem cells (hiPSCs) and other cell types used in cell-based...
- Federal Grant Award Summary Award Details: Funding Agency: National Institute of General Medical Sciences (NIGMS) Program: Biomedical Research and Research Training (CFDA 93.859) Awardee: Andson Biotech Inc. Total Obligated Funding: $302,671.00 Award Date: August 2, 2025 Performance Period: August 2, 2025 – August 1, 2026 Location: Georgia, USA Project Scope: This Project Grant funds the development of an innovative real-time mass spectrometry platform designed to address critical gaps in...
- Federal Grant Award Summary Newomics Inc. received a $1.0 million Small Business Innovation Research (SBIR) Phase II Project Grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), effective September 1, 2025 through August 31, 2027. The award funds the development and commercialization of the UniESI platform, an integrated imaging-mass spectrometry front-end system designed for native spray mass...
- Federal Project Grant Award Summary Vivid Bioinnovations, PBC (operating as Fluid Discovery, Inc.) received a $306,872 Project Grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) for the period August 1, 2025 through July 31, 2026. The award supports development of a commercial prototype for an ultrahigh-throughput biocatalyst evolution platform that combines precision nanoliter fluid handling, label-free...
- Federal Grant Award Summary Xgenomes Corp. received a $349,280 Project Grant from the National Institute of General Medical Sciences under the Biomedical Research and Research Training program (CFDA 93.859), awarded on September 15, 2025, with a completion date of September 14, 2026. The award funds the development of machine learning algorithms designed to advance single molecule localization microscopy (SMLM) technology, enabling ultra-high-density and ultra-high-precision analysis of...
- Federal Grant Award Summary Electronic Biosciences, Inc. received a $418,854 Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) for the period June 8, 2026 through May 31, 2028. The company is developing a next-generation single-molecule protein sequencing platform designed to overcome critical limitations in current oncoproteomics technologies. The platform will enable direct, high-accuracy sequencing of individual proteins...
- Federal Grant Award Summary Vivid Bioinnovations, PBC (operating as Fluid Discovery, Inc.) received a $613,742 Fast-Track Small Business Innovation Research (SBIR) award from the National Institute on Aging under the Aging Research program (CFDA 93.866), with an award date of September 12, 2025, and completion date of February 28, 2027. The award supports the commercialization and development of FIND-SEQ, a novel cell sorting technology that enables the isolation of rare cells or nuclei based on...
- Federal Grant Award Summary Micropure Genomics Inc. received a $291,232 Project Grant award from the National Human Genome Research Institute (NHGRI) under the Human Genome Research program (CFDA 93.172), effective September 17, 2025, with a completion date of August 31, 2026. The award supports the development and validation of an automated microfluidic size selection platform, designated mPREP, that utilizes patented electro-hydrodynamic trapping technology to enable rapid, bead-less, and...
- Federal Grant Award Summary Sinopia Biosciences Inc. received a $350,000 Project Grant from the National Institute of General Medical Sciences under the Biomedical Research and Research Training program (CFDA 93.859) awarded August 1, 2025, with completion targeted for July 31, 2026. The award supports the development of neural network models and computational workflows to enable efficient metabolomic characterization of large compound libraries for data-driven drug discovery (D4). Sinopia...
Sansimeon Inc. received a $382,798 Project Grant from the National Institute of General Medical Sciences under the Biomedical Research and Research Training program (CFDA 93.859) awarded on June 15, 2026, with completion targeted for May 31, 2027. The company is developing a fully integrated, turnkey platform designed to address critical limitations in single-cell sequencing (SC-SEQ) for clinical and translational research applications. The platform consolidates multiple preparation steps—including red blood cell and platelet removal, cell enrichment, multiplexed tagging, and CITE-SEQ (cellular indexing of transcriptomes and epitopes by sequencing) labeling—into a streamlined one-step workflow that eliminates centrifugation and reduces hands-on time requirements. The deliverables include development and validation of unified protocols for SC-SEQ multiplexing and cell enrichment using peripheral whole blood samples, followed by construction of an automated benchtop instrument and injection-molded microfluidic cartridge to enable standardized, reproducible sample preparation. The platform is engineered to process up to 100 million cells per run with significantly improved cell-bead pairing efficiency, with particular applicability to detecting rare cell populations critical for immunotherapy development, precision diagnostics, and minimal residual disease detection. The integrated system addresses reproducibility and scalability challenges that currently limit SC-SEQ adoption in clinical settings.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $382.8k | 6/16/26 |